BioStock: Wnt follows the authorities’ advice and pauses recruitment to phase II study
Monday saw the news that biotech WntResearch has decided to pause the recruitment of patients to its phase II study in Spain and Hungary. The reason is the ongoing Covid-19 pandemic, which places a heavy burden on the healthcare system of both those countries. Therefore, in accordance with the advice of the national authorities, the company has chosen to suspend patient recruitment activities in order not to add to the burden placed on the participating clinics or jeopardise the study’s integrity. BioStock had the chance to ask a couple of questions of CEO Peter Morsing about the decision.
Read the full article and interview at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se